Do GLP-1 users skip strength training? new survey aims to find out

NCT ID NCT07702461

First seen Jul 14, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This study surveys adults taking GLP-1 medications (like semaglutide or tirzepatide) for diabetes or weight loss to understand their resistance training habits before and after starting the drug. The goal is to learn how often people strength train, what their workouts look like, and what barriers they face. Findings could help healthcare providers create better exercise guidance to protect muscle mass during weight loss.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
GLP-1 receptor agonist (e.g., semaglutide, liraglutide, tirzepatide)
What this could lead to
If this study reveals common gaps in resistance training among GLP-1 users, it could help doctors design better exercise recommendations to preserve muscle mass and physical function.
What could go wrong
This is an observational survey, not a treatment trial, so it cannot prove cause and effect. Results rely on self-reported habits, which may not be fully accurate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES (DM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus Motor Activity Obesity obesity disorder Overweight Sarcopenia type 2 diabetes mellitus Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The Ohio State University

    RECRUITING

    Columbus, Ohio, 43210, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.